Inhibition of circulating PCSK9 using novel humanized monoclonal antibodies leads to important reductions in LDL-C in patients on and off statins.9,10 Recent preclinical studies have shown that PCSK9 expression increases during systemic inflammation11 and with podocyte injury.12 Both are central features of CKD and contributed to by ET-1 (endothelin-1).13 The gene discussed is EDN1; the disease is chronic kidney disease.